EGFR and non-small cell lung carcinoma: Consistent with our research, Xu et al. [37] reported that patients with a short-term response to EGFR-TKIs (PFS < 6 months) had a high incidence of TP53 co-mutation using NGS (88% vs. 13%, p < 0.001) in metastatic NSCLC patients with EGFR exon 21 and exon 19 mutations, indicating that TP53 co-mutation is a poor prognostic factor in EGFR-mutant NSCLC.